Viz.ai, a leader in AI-powered disease detection and care coordination, today announced a multi-year agreement with Bristol Myers Squibb, a global biopharmaceutical company, to develop an artificial intelligence (AI) algorithm and provider workflow software (Viz TM HCM) designed to identify and classify patients who may require re-evaluation for hypertrophic cardiomyopathy.

The release in the original language is the official and authorized version thereof. This translation is only a means of help and must be compared with the text in the original language, which is the only version of the text that will have legal validity.

Contacts
Ariane Lovell
ariane.lovell@finnpartners.com

Source:businesswire.com